{"nctId":"NCT03034772","briefTitle":"Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration","startDateStruct":{"date":"2017-02-08","type":"ACTUAL"},"conditions":["Neovascular Age-related Macular Degeneration","Wet Macular Degeneration"],"count":52,"armGroups":[{"label":"Dorzolamide-timolol","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dorzolamide-timolol"]},{"label":"Artificial tears","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Artificial tears"]}],"interventions":[{"name":"Dorzolamide-timolol","otherNames":["Cosopt"]},{"name":"Artificial tears","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Active choroidal neovascularization (CNV) due to AMD.\n2. Prior treatment with at least 4 injections of anti-VEGF agents in the past 6 months and persistent intraretinal and/or subretinal fluid on SD-OCT at each visit during this period.\n3. Baseline CST ≥ 270 µm on SD-OCT automated retinal thickness map.\n4. Injection of the same anti-VEGF agent at each of the two visits immediately preceding study enrollment.\n5. Time interval of 5 weeks (± 1 week) between visits for at least two visits immediately preceding study enrollment.\n6. Subjects of either gender aged ≥ 45 years.\n7. Provide written informed consent\n8. Ability to comply with study and follow-up procedures and return for study visits.\n\nExclusion Criteria:\n\n1. History of uveitis.\n2. Presence of intraocular inflammation, significant epiretinal membrane (causing distortion of macular anatomy per investigator discretion), significant vitreomacular traction (per investigator discretion), macular hole, or vitreous hemorrhage.\n3. Any ophthalmic surgery within previous 6 months, including cataract extraction.\n4. Any history of vitrectomy or glaucoma surgery (e.g., trabeculectomy, tube shunt).\n5. Current prescription eye drop usage (e.g., glaucoma drops, corticosteroid drops, etc.).\n6. Any contraindication for topical use of a beta-blocker (e.g., bradycardia, decompensated heart failure, chronic obstructive pulmonary disease, reactive airway disease, asthma, etc.).\n7. Any history of sulfonamide allergy.","healthyVolunteers":false,"sex":"ALL","minimumAge":"45 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Mean Central Subfield Thickness (CST)","description":"Change in mean CST on spectral domain optical coherence tomography from baseline to the final visit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.6","spread":"54"},{"groupId":"OG001","value":"1.7","spread":"52.3"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Maximum Subretinal Fluid (SRF) Height","description":"Change in mean maximum SRF height on spectral domain optical coherence tomography from baseline to final visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.4","spread":"55"},{"groupId":"OG001","value":"-22.2","spread":"56"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Maximum Pigment Epithelial Detachment (PED) Height","description":"Change in mean maximum PED height on spectral domain optical coherence tomography from baseline to final visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.1","spread":"65"},{"groupId":"OG001","value":"1.1","spread":"16"}]}]}]},{"type":"SECONDARY","title":"Change in Visual Acuity","description":"Change in mean best available visual acuity from baseline to final visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.031","spread":"0.15"},{"groupId":"OG001","value":"0.018","spread":"0.16"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Intraocular Pressure (IOP)","description":"Change in mean IOP from baseline to final visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.81","spread":"3.8"},{"groupId":"OG001","value":"-0.78","spread":"2.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":27},"commonTop":["Eyelid edema"]}}}